Molecular alterations in meningiomas: association with clinical data

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Meningiomas are the most common primary tumors of the central nervous system.
• Understanding the genetic underpinnings of meningioma progression is crucial for improved diagnostics and therapeutics.
• Previous studies suggest chromosomal deletions are involved in meningioma development, but specific correlations require further investigation.

Purpose of the Study:

• To investigate the frequency of deletions on chromosomes 1, 9, 10, 14, 18, and 22 in meningiomas.
• To correlate these genetic alterations with tumor grade, size, histological subtype, and localization.
• To identify potential genetic markers associated with meningioma pathogenesis and progression.

Main Methods:

• Analysis of paired normal and tumor DNA from 75 benign and 15 atypical meningiomas.
• Utilized 24 microsatellite markers and PCR techniques to assess loss of heterozygosity (LOH).
• Statistical analyses were performed to correlate genetic findings with clinical and pathological data.

Main Results:

• Deletions on chromosomes 14 and 18 were significantly associated with higher tumor grade (p = 0.048 and p = 0.03).
• Loss of heterozygosity on chromosome 14 correlated with increased tumor size (p = 0.049).
• Chromosome 22 LOH was the most frequent abnormality (67%) and associated with histological subtype and tumor localization (p = 0.001 and p = 0.0004).
• A marginally increased frequency of LOH on chromosome 9 was observed in atypical meningiomas (p = 0.06).

Conclusions:

• Allelic loss on chromosomes 9, 10, 14, 18, and 22 are potentially associated with meningioma pathogenesis and progression.
• Specific chromosomal deletions correlate with key clinical and pathological features, offering insights into tumor behavior.
• These findings may contribute to developing more precise diagnostic and prognostic tools for meningioma patients.